The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015
Abstract Introduction This article reviews the work done in the Alzheimer's Disease Neuroimaging Initiative positron emission tomography (ADNI PET) core over the past 5 years, largely concerning techniques, methods, and results related to amyloid imaging in ADNI. Methods The PET Core has used [...
Gespeichert in:
| Veröffentlicht in: | Alzheimer's & dementia 2015-07, Vol.11 (7), p.757-771 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 771 |
|---|---|
| container_issue | 7 |
| container_start_page | 757 |
| container_title | Alzheimer's & dementia |
| container_volume | 11 |
| creator | Jagust, William J Landau, Susan M Koeppe, Robert A Reiman, Eric M Chen, Kewei Mathis, Chester A Price, Julie C Foster, Norman L Wang, Angela Y |
| description | Abstract Introduction This article reviews the work done in the Alzheimer's Disease Neuroimaging Initiative positron emission tomography (ADNI PET) core over the past 5 years, largely concerning techniques, methods, and results related to amyloid imaging in ADNI. Methods The PET Core has used [18 F]florbetapir routinely on ADNI participants, with over 1600 scans available for download. Four different laboratories are involved in data analysis, and have examined factors such as longitudinal florbetapir analysis, use of [18 F]fluorodeoxyglucose (FDG)-PET in clinical trials, and relationships between different biomarkers and cognition. Results Converging evidence from the PET Core has indicated that cross-sectional and longitudinal florbetapir analyses require different reference regions. Studies have also examined the relationship between florbetapir data obtained immediately after injection, which reflects perfusion, and FDG-PET results. Finally, standardization has included the translation of florbetapir PET data to a centiloid scale. Conclusion The PET Core has demonstrated a variety of methods for the standardization of biomarkers such as florbetapir PET in a multicenter setting. |
| doi_str_mv | 10.1016/j.jalz.2015.05.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1698021961</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1552526015001673</els_id><sourcerecordid>1698021961</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5261-a9f24a9bd2a5ad9a143606f7e468966afcc50f61f2a100b3666e83d123f76ee23</originalsourceid><addsrcrecordid>eNqNUU1PwzAMjRCIjY8_wAH1BpcNO22zlQNiGl9DEyAxLlyirHO3lK6FZAWNX0-iDs5Ilm1F7z07z4wdIXQRUJzl3VwV310OGHfBBeAWa2Mc807Me8n2Xy-gxfaszQEi6GO8y1pcYBKFiG12OVlQMCi-F6SXZE5scKUtKUvBA9Wm0ks11-U8GJV6pdVKf1LAg6frSTCsDJ0HfvIB28lUYelwU_fZy831ZHjXGT_ejoaDcSd1C2BHJRmPVDKdcRWrWaIwCgWIrEeR6CdCqCxNY8gEZlwhwDQUQlA_nCEPs54g4uE-O2103031UZNdyaW2KRWFKqmqrUSR9IFjItBBeQNNTWWtoUy-G_cTs5YI0jsnc-mdk35_CS7Ak443-vV0SbM_yq9VDjBoAF-6oPU_JOVg_Hp_75J_g7gZctFokHPqU5ORaaFLnarijdZk86o2pTNRorRcgnz2B_T3Q88WvTD8AUzTkBg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1698021961</pqid></control><display><type>article</type><title>The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Jagust, William J ; Landau, Susan M ; Koeppe, Robert A ; Reiman, Eric M ; Chen, Kewei ; Mathis, Chester A ; Price, Julie C ; Foster, Norman L ; Wang, Angela Y</creator><creatorcontrib>Jagust, William J ; Landau, Susan M ; Koeppe, Robert A ; Reiman, Eric M ; Chen, Kewei ; Mathis, Chester A ; Price, Julie C ; Foster, Norman L ; Wang, Angela Y</creatorcontrib><description>Abstract Introduction This article reviews the work done in the Alzheimer's Disease Neuroimaging Initiative positron emission tomography (ADNI PET) core over the past 5 years, largely concerning techniques, methods, and results related to amyloid imaging in ADNI. Methods The PET Core has used [18 F]florbetapir routinely on ADNI participants, with over 1600 scans available for download. Four different laboratories are involved in data analysis, and have examined factors such as longitudinal florbetapir analysis, use of [18 F]fluorodeoxyglucose (FDG)-PET in clinical trials, and relationships between different biomarkers and cognition. Results Converging evidence from the PET Core has indicated that cross-sectional and longitudinal florbetapir analyses require different reference regions. Studies have also examined the relationship between florbetapir data obtained immediately after injection, which reflects perfusion, and FDG-PET results. Finally, standardization has included the translation of florbetapir PET data to a centiloid scale. Conclusion The PET Core has demonstrated a variety of methods for the standardization of biomarkers such as florbetapir PET in a multicenter setting.</description><identifier>ISSN: 1552-5260</identifier><identifier>EISSN: 1552-5279</identifier><identifier>DOI: 10.1016/j.jalz.2015.05.001</identifier><identifier>PMID: 26194311</identifier><language>eng</language><publisher>United States</publisher><subject>Alzheimer Disease - complications ; Alzheimer Disease - diagnosis ; Alzheimer Disease - genetics ; Alzheimer's disease ; Amyloid ; Apolipoprotein E4 - genetics ; Brain - diagnostic imaging ; Brain Mapping ; Cognition Disorders - etiology ; Fluorodeoxyglucose ; Fluorodeoxyglucose F18 - pharmacokinetics ; Humans ; Imaging, Three-Dimensional ; Longitudinal Studies ; Mild cognitive impairment ; Neurology ; PET imaging ; Positron-Emission Tomography</subject><ispartof>Alzheimer's & dementia, 2015-07, Vol.11 (7), p.757-771</ispartof><rights>The Alzheimer's Association</rights><rights>2015 The Alzheimer's Association</rights><rights>Copyright © 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5261-a9f24a9bd2a5ad9a143606f7e468966afcc50f61f2a100b3666e83d123f76ee23</citedby><cites>FETCH-LOGICAL-c5261-a9f24a9bd2a5ad9a143606f7e468966afcc50f61f2a100b3666e83d123f76ee23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1016%2Fj.jalz.2015.05.001$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1016%2Fj.jalz.2015.05.001$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26194311$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jagust, William J</creatorcontrib><creatorcontrib>Landau, Susan M</creatorcontrib><creatorcontrib>Koeppe, Robert A</creatorcontrib><creatorcontrib>Reiman, Eric M</creatorcontrib><creatorcontrib>Chen, Kewei</creatorcontrib><creatorcontrib>Mathis, Chester A</creatorcontrib><creatorcontrib>Price, Julie C</creatorcontrib><creatorcontrib>Foster, Norman L</creatorcontrib><creatorcontrib>Wang, Angela Y</creatorcontrib><title>The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015</title><title>Alzheimer's & dementia</title><addtitle>Alzheimers Dement</addtitle><description>Abstract Introduction This article reviews the work done in the Alzheimer's Disease Neuroimaging Initiative positron emission tomography (ADNI PET) core over the past 5 years, largely concerning techniques, methods, and results related to amyloid imaging in ADNI. Methods The PET Core has used [18 F]florbetapir routinely on ADNI participants, with over 1600 scans available for download. Four different laboratories are involved in data analysis, and have examined factors such as longitudinal florbetapir analysis, use of [18 F]fluorodeoxyglucose (FDG)-PET in clinical trials, and relationships between different biomarkers and cognition. Results Converging evidence from the PET Core has indicated that cross-sectional and longitudinal florbetapir analyses require different reference regions. Studies have also examined the relationship between florbetapir data obtained immediately after injection, which reflects perfusion, and FDG-PET results. Finally, standardization has included the translation of florbetapir PET data to a centiloid scale. Conclusion The PET Core has demonstrated a variety of methods for the standardization of biomarkers such as florbetapir PET in a multicenter setting.</description><subject>Alzheimer Disease - complications</subject><subject>Alzheimer Disease - diagnosis</subject><subject>Alzheimer Disease - genetics</subject><subject>Alzheimer's disease</subject><subject>Amyloid</subject><subject>Apolipoprotein E4 - genetics</subject><subject>Brain - diagnostic imaging</subject><subject>Brain Mapping</subject><subject>Cognition Disorders - etiology</subject><subject>Fluorodeoxyglucose</subject><subject>Fluorodeoxyglucose F18 - pharmacokinetics</subject><subject>Humans</subject><subject>Imaging, Three-Dimensional</subject><subject>Longitudinal Studies</subject><subject>Mild cognitive impairment</subject><subject>Neurology</subject><subject>PET imaging</subject><subject>Positron-Emission Tomography</subject><issn>1552-5260</issn><issn>1552-5279</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUU1PwzAMjRCIjY8_wAH1BpcNO22zlQNiGl9DEyAxLlyirHO3lK6FZAWNX0-iDs5Ilm1F7z07z4wdIXQRUJzl3VwV310OGHfBBeAWa2Mc807Me8n2Xy-gxfaszQEi6GO8y1pcYBKFiG12OVlQMCi-F6SXZE5scKUtKUvBA9Wm0ks11-U8GJV6pdVKf1LAg6frSTCsDJ0HfvIB28lUYelwU_fZy831ZHjXGT_ejoaDcSd1C2BHJRmPVDKdcRWrWaIwCgWIrEeR6CdCqCxNY8gEZlwhwDQUQlA_nCEPs54g4uE-O2103031UZNdyaW2KRWFKqmqrUSR9IFjItBBeQNNTWWtoUy-G_cTs5YI0jsnc-mdk35_CS7Ak443-vV0SbM_yq9VDjBoAF-6oPU_JOVg_Hp_75J_g7gZctFokHPqU5ORaaFLnarijdZk86o2pTNRorRcgnz2B_T3Q88WvTD8AUzTkBg</recordid><startdate>201507</startdate><enddate>201507</enddate><creator>Jagust, William J</creator><creator>Landau, Susan M</creator><creator>Koeppe, Robert A</creator><creator>Reiman, Eric M</creator><creator>Chen, Kewei</creator><creator>Mathis, Chester A</creator><creator>Price, Julie C</creator><creator>Foster, Norman L</creator><creator>Wang, Angela Y</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201507</creationdate><title>The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015</title><author>Jagust, William J ; Landau, Susan M ; Koeppe, Robert A ; Reiman, Eric M ; Chen, Kewei ; Mathis, Chester A ; Price, Julie C ; Foster, Norman L ; Wang, Angela Y</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5261-a9f24a9bd2a5ad9a143606f7e468966afcc50f61f2a100b3666e83d123f76ee23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Alzheimer Disease - complications</topic><topic>Alzheimer Disease - diagnosis</topic><topic>Alzheimer Disease - genetics</topic><topic>Alzheimer's disease</topic><topic>Amyloid</topic><topic>Apolipoprotein E4 - genetics</topic><topic>Brain - diagnostic imaging</topic><topic>Brain Mapping</topic><topic>Cognition Disorders - etiology</topic><topic>Fluorodeoxyglucose</topic><topic>Fluorodeoxyglucose F18 - pharmacokinetics</topic><topic>Humans</topic><topic>Imaging, Three-Dimensional</topic><topic>Longitudinal Studies</topic><topic>Mild cognitive impairment</topic><topic>Neurology</topic><topic>PET imaging</topic><topic>Positron-Emission Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jagust, William J</creatorcontrib><creatorcontrib>Landau, Susan M</creatorcontrib><creatorcontrib>Koeppe, Robert A</creatorcontrib><creatorcontrib>Reiman, Eric M</creatorcontrib><creatorcontrib>Chen, Kewei</creatorcontrib><creatorcontrib>Mathis, Chester A</creatorcontrib><creatorcontrib>Price, Julie C</creatorcontrib><creatorcontrib>Foster, Norman L</creatorcontrib><creatorcontrib>Wang, Angela Y</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alzheimer's & dementia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jagust, William J</au><au>Landau, Susan M</au><au>Koeppe, Robert A</au><au>Reiman, Eric M</au><au>Chen, Kewei</au><au>Mathis, Chester A</au><au>Price, Julie C</au><au>Foster, Norman L</au><au>Wang, Angela Y</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015</atitle><jtitle>Alzheimer's & dementia</jtitle><addtitle>Alzheimers Dement</addtitle><date>2015-07</date><risdate>2015</risdate><volume>11</volume><issue>7</issue><spage>757</spage><epage>771</epage><pages>757-771</pages><issn>1552-5260</issn><eissn>1552-5279</eissn><abstract>Abstract Introduction This article reviews the work done in the Alzheimer's Disease Neuroimaging Initiative positron emission tomography (ADNI PET) core over the past 5 years, largely concerning techniques, methods, and results related to amyloid imaging in ADNI. Methods The PET Core has used [18 F]florbetapir routinely on ADNI participants, with over 1600 scans available for download. Four different laboratories are involved in data analysis, and have examined factors such as longitudinal florbetapir analysis, use of [18 F]fluorodeoxyglucose (FDG)-PET in clinical trials, and relationships between different biomarkers and cognition. Results Converging evidence from the PET Core has indicated that cross-sectional and longitudinal florbetapir analyses require different reference regions. Studies have also examined the relationship between florbetapir data obtained immediately after injection, which reflects perfusion, and FDG-PET results. Finally, standardization has included the translation of florbetapir PET data to a centiloid scale. Conclusion The PET Core has demonstrated a variety of methods for the standardization of biomarkers such as florbetapir PET in a multicenter setting.</abstract><cop>United States</cop><pmid>26194311</pmid><doi>10.1016/j.jalz.2015.05.001</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1552-5260 |
| ispartof | Alzheimer's & dementia, 2015-07, Vol.11 (7), p.757-771 |
| issn | 1552-5260 1552-5279 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1698021961 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Alzheimer Disease - complications Alzheimer Disease - diagnosis Alzheimer Disease - genetics Alzheimer's disease Amyloid Apolipoprotein E4 - genetics Brain - diagnostic imaging Brain Mapping Cognition Disorders - etiology Fluorodeoxyglucose Fluorodeoxyglucose F18 - pharmacokinetics Humans Imaging, Three-Dimensional Longitudinal Studies Mild cognitive impairment Neurology PET imaging Positron-Emission Tomography |
| title | The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T14%3A24%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Alzheimer's%20Disease%20Neuroimaging%20Initiative%202%20PET%20Core:%202015&rft.jtitle=Alzheimer's%20&%20dementia&rft.au=Jagust,%20William%20J&rft.date=2015-07&rft.volume=11&rft.issue=7&rft.spage=757&rft.epage=771&rft.pages=757-771&rft.issn=1552-5260&rft.eissn=1552-5279&rft_id=info:doi/10.1016/j.jalz.2015.05.001&rft_dat=%3Cproquest_cross%3E1698021961%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1698021961&rft_id=info:pmid/26194311&rft_els_id=1_s2_0_S1552526015001673&rfr_iscdi=true |